Pharmsville Balance Sheet Health
Financial Health criteria checks 5/6
Pharmsville has a total shareholder equity of ₩63.7B and total debt of ₩545.4M, which brings its debt-to-equity ratio to 0.9%. Its total assets and total liabilities are ₩69.5B and ₩5.8B respectively.
Key information
0.9%
Debt to equity ratio
₩545.44m
Debt
Interest coverage ratio | n/a |
Cash | ₩39.25b |
Equity | ₩63.69b |
Total liabilities | ₩5.78b |
Total assets | ₩69.47b |
Recent financial health updates
Pharmsville (KOSDAQ:318010) Has A Pretty Healthy Balance Sheet
Mar 31Here's Why Pharmsville (KOSDAQ:318010) Can Manage Its Debt Responsibly
Dec 24Recent updates
Some Pharmsville Co., Ltd. (KOSDAQ:318010) Shareholders Look For Exit As Shares Take 26% Pounding
Dec 09Unpleasant Surprises Could Be In Store For Pharmsville Co., Ltd.'s (KOSDAQ:318010) Shares
Oct 14Pharmsville's (KOSDAQ:318010) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Mar 28Pharmsville (KOSDAQ:318010) Has A Pretty Healthy Balance Sheet
Mar 31We're Watching These Trends At Pharmsville (KOSDAQ:318010)
Mar 03Pharmsville's (KOSDAQ:318010) Shareholders Are Down 20% On Their Shares
Feb 10Factors Income Investors Should Consider Before Adding Pharmsville Co., Ltd. (KOSDAQ:318010) To Their Portfolio
Jan 20Here's Why Pharmsville (KOSDAQ:318010) Can Manage Its Debt Responsibly
Dec 24Is Pharmsville Co., Ltd. (KOSDAQ:318010) A High Quality Stock To Own?
Nov 26Financial Position Analysis
Short Term Liabilities: A318010's short term assets (₩43.3B) exceed its short term liabilities (₩3.8B).
Long Term Liabilities: A318010's short term assets (₩43.3B) exceed its long term liabilities (₩1.9B).
Debt to Equity History and Analysis
Debt Level: A318010 has more cash than its total debt.
Reducing Debt: A318010's debt to equity ratio has reduced from 8.4% to 0.9% over the past 5 years.
Debt Coverage: A318010's debt is well covered by operating cash flow (419.7%).
Interest Coverage: Insufficient data to determine if A318010's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 19:50 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmsville Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kyung-rae Han | Daishin Securities Co. Ltd. |
Jongsun Park | Eugene Investment & Securities Co Ltd. |